SEARCH

SEARCH BY CITATION

References

  • 1
    Weber EJ, Silverman RA, Callaham ML, Pollack CV, Woodruff PG, Clark S et al. A prospective multicenter study of factors associated with hospital admission among adults with acute asthma. Am J Med 2002;113: 371378.
  • 2
    Hartert TV, Speroff T, Togias A, Mitchel EF Jr, Snowden MS, Dittus RS et al. Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma. Ann Allergy Asthma Immunol 2002;89: 467473.
  • 3
    Pollack CV Jr, Pollack ES, Baren JM, Smith SR, Woodruff PG, Clark S et al. Multicenter Airway Research Collaboration Investigators. A prospective multicenter study of patient factors associated with hospital admission from the emergency department among children with acute asthma. Arch Pediatr Adolesc Med 2002;156: 934940.
  • 4
    Sidebotham HJ, Roche WR. Asthma deaths; persistent and preventable mortality. Histopathology 2003;43: 105117.
  • 5
    Jalaludin BB, Smith MA, Chey T, Orr NJ, Smith WT, Leeder SR. Risk factors for asthma deaths: a population-based, case-control study. Aust N Z J Public Health 1999;23: 595600.
  • 6
    Lee P, Abisheganaden J, Chee CB, Wang YT. A new asthma severity index: a predictor of near-fatal asthma? Eur Respir J 2001;18: 272278.
  • 7
    Burr ML, Davies BH, Hoare A, Jones A, Williamson IJ, Holgate SK et al. A confidential inquiry into asthma deaths in Wales. Thorax 1999;54: 985989.
  • 8
    Tough SC, Hessel PA, Ruff M, Green FH, Mitchell I, Butt JC. Features that distinguish those who die from asthma from community controls with asthma. J Asthma 1998;35: 657665.
  • 9
    Turner MO, Noertjojo K, Vedal S, Bai T, Crump S, Fitzgerald JM. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. Am J Respir Crit Care Med 1998;157: 18041809.
  • 10
    Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NIH Publication 02-3659 issued January 1995 (Updated 2002, 2003). At: http://www.ginasthma.com (accessed 26 May 2004).
  • 11
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108: 184190.
  • 12
    Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18: 254261. Erratum in: Eur Respir J 2001;18: 739–740.
  • 13
    Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59: 701708.
  • 14
    Vignola AM, Humbert M, Bousquet J, Boulet L-P, Hedgecock S, Blogg M et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis (SOLAR). Allergy 2004;59: 709717.
  • 15
    Holgate ST, Chuchalin AG, Hébert J, Lotvall J, Persson GB, Chung KF et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34: 632638.
  • 16
    Buhl R, Hanf G, Solèr M, Bensch G, Wolfe J, Everhard F et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002;20: 10881094.
  • 17
    Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003;111: 278284.
  • 18
    Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001;17: 233240.
  • 19
    Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111: 8790.
  • 20
    Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125: 13781386.
  • 21
    Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003;19: 491498.
  • 22
    Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91: 154159.
  • 23
    Buhl R, Solèr M, Matz J, Townley R, O'Brien J, Noga O et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20: 7378.
  • 24
    Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108: E36.
  • 25
    Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9: 636642.